Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
61.4M
-
Number of holders
-
238
-
Total 13F shares, excl. options
-
61.6M
-
Shares change
-
-1.54M
-
Total reported value, excl. options
-
$2.77B
-
Value change
-
-$40.7M
-
Put/Call ratio
-
3.14
-
Number of buys
-
151
-
Number of sells
-
-87
-
Price
-
$45.00
Significant Holders of Protagonist Therapeutics, Inc - Common Stock (PTGX) as of Q3 2024
271 filings reported holding PTGX - Protagonist Therapeutics, Inc - Common Stock as of Q3 2024.
Protagonist Therapeutics, Inc - Common Stock (PTGX) has 238 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 61.6M shares
.
Largest 10 shareholders include BlackRock, Inc. (10.2M shares), FARALLON CAPITAL MANAGEMENT LLC (5.86M shares), RTW INVESTMENTS, LP (5.43M shares), VANGUARD GROUP INC (4.22M shares), STATE STREET CORP (3.18M shares), JOHNSON & JOHNSON (2.45M shares), BVF INC/IL (1.85M shares), Jefferies Financial Group Inc. (1.81M shares), Pacer Advisors, Inc. (1.73M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.37M shares).
This table shows the top 238 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.